LRIG3 and central nervous system cancer: In summation, we verified for the first time that sLRIG3 has the capability of being released from glioma cells and exists in the patient serum and glioma cystic fluid, and both LRIG3 and sLRIG3 significantly inhibit the proliferation and invasion capabilities of glioma cells both in vitro and in vivo through inhibiting MET/PI3K/Akt pathway.